The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US
about
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonCan we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) StudyCost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review.Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settingsReview of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model.Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVALPredictors of anticoagulation in hospice patients with lung cancer.Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular eventsPlasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.Costs and clinical consequences of suboptimal atrial fibrillation management.Monitoring of international normalized ratios: comparison of community nurses with family physicians.Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the NetherlandsCost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden.Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemiaThe cost-effectiveness of Maze procedures using ablation techniques at the time of mitral valve surgery.Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece.Penny-wise, pound-foolish? Highmark Medicare Services' proposal for anticoagulation clinic reimbursement.Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation.Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital.Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.Designing and Implementing an Electronic Patient Registry to Improve Warfarin Monitoring in the Ambulatory Setting.Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective.Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore.A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark.Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed.Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.Patient preferences and willingness to pay for different options of anticoagulant therapy.Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.Evaluating the role of clinical pharmacists in pre-procedural anticoagulation management.Cost-effectiveness of the pharmacist-assisted warfarin monitoring program at a Medical Center in Taiwan.Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
P2860
Q27006860-CF070915-B3AE-4D7A-BE43-3F1D953ABE76Q33776805-14922FAA-376A-4C60-A13E-21C42D741F0CQ34180151-71220C39-B84F-4E94-B60A-8E6BCB8FC001Q34604533-654F2AF9-088B-4006-8F3C-A55D513C6BE0Q34680367-0ED32CFC-B279-41B7-AF76-AF0A4214CC9DQ34834319-542C830F-C3F5-4D1D-BE3F-32C248614EBAQ35099559-D8A6383F-E9D2-4CF1-AEC4-3C59EFD14EE5Q35156374-D0C1FD6C-ACDB-4BDF-8A1C-18537A59A3FAQ35752981-6327547C-A78B-4A2B-BC70-CF6894368D5DQ35795404-9B107F20-D9C8-46E6-995C-1B3F6D4690E9Q35841464-E490FF19-E0CC-4EF0-BB95-C07D791234DFQ35885128-D54A2DA1-6C2A-4262-A5D7-B265C2ECB5DEQ36164026-96099A20-6728-4062-B754-B7A7CDA2594DQ36203436-E19BF228-364E-4932-B735-F02C8B4E807CQ36363175-0730823C-61A9-4E75-BF7A-A59F75CAE9D1Q37052293-2FD08E40-5C50-4C1B-B371-F908B0280063Q37299398-1308A6F8-846E-4AE1-9852-9AF7448D91F3Q37303759-7DA304FE-B830-463E-97C1-A2ACD186915AQ37612072-CAE64E44-EF51-414C-B901-D6FD392C349FQ37616932-0817BFD5-A844-4FC0-ACCA-9C4B5225BE59Q37717892-04B2B6F6-6E09-489E-A44C-46511D6E0416Q37982206-301B3819-7DD8-49CB-8029-8FB344F2B5E1Q38080912-C1FE8F00-1157-4DD0-9097-3A8C22E04014Q38097972-19AE801F-5EB7-4415-85B1-8B63A1773BCBQ38110182-FA03F2A8-7BC1-4F6C-8C00-6BB015D883EFQ38371289-31B26683-83B5-48E6-91F1-A16F750408FCQ38598138-5F65B62E-C8DF-4024-A055-B0EAC5DC0621Q38710143-A3A3DC37-1558-4B14-B01C-FCC4E7DB8EA7Q39325539-EF75955B-6BB8-445F-8595-B2D2CA82DDDBQ39556840-B9EA081B-06DB-411D-9DF9-D67DECCE24B0Q40973888-E34AAE40-DD55-414D-BA95-9AB0E30DCDE9Q41535294-DC2F615C-B7BD-43ED-8DFC-B76000A2A1F7Q42377391-94309007-5D21-4C20-80E8-FF2062794234Q44769550-919A915E-D344-405C-B0DF-794CAD8382CAQ45881407-5DCB3E3A-A3D6-43FC-B176-FCFFBE2355B9Q47768172-E9E30485-EEC5-4EA2-B872-178469DEED87Q48149969-0FBDE7B9-37DB-4C9B-9215-2F77158EABECQ49539661-7DCBF741-E48D-4441-82C6-E286CC7C94C0Q50100179-93E80FDC-FB31-49DE-8F68-0604305EAD79Q51819093-B061D503-CA18-4FF9-BDDF-2F6EF8BDE01A
P2860
The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US
description
2006 թուականին հրատարակուած գիտական յօդուած
@hyw
2006 թվականին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im Januar 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2006)
@en
vedecký článok (publikovaný 2006)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd in 2006)
@nl
наукова стаття, опублікована у 2006
@uk
مقالة علمية (نشرت عام 2006)
@ar
name
The cost effectiveness of anti ...... high risk of stroke in the US
@ast
The cost effectiveness of anti ...... high risk of stroke in the US
@en
The cost effectiveness of anti ...... high risk of stroke in the US
@nl
type
label
The cost effectiveness of anti ...... high risk of stroke in the US
@ast
The cost effectiveness of anti ...... high risk of stroke in the US
@en
The cost effectiveness of anti ...... high risk of stroke in the US
@nl
prefLabel
The cost effectiveness of anti ...... high risk of stroke in the US
@ast
The cost effectiveness of anti ...... high risk of stroke in the US
@en
The cost effectiveness of anti ...... high risk of stroke in the US
@nl
P2093
P921
P1433
P1476
The cost effectiveness of anti ...... high risk of stroke in the US
@en
P2093
Heather Ulrich
Patrick W Sullivan
Samuel L Ellis
Thomas W Arant
P2860
P304
P356
10.2165/00019053-200624100-00009
P407
P577
2006-01-01T00:00:00Z
P6179
1043521649